AR127610A1 - Método de producción de un conjugado de anticuerpo-péptido - Google Patents

Método de producción de un conjugado de anticuerpo-péptido

Info

Publication number
AR127610A1
AR127610A1 ARP220103063A ARP220103063A AR127610A1 AR 127610 A1 AR127610 A1 AR 127610A1 AR P220103063 A ARP220103063 A AR P220103063A AR P220103063 A ARP220103063 A AR P220103063A AR 127610 A1 AR127610 A1 AR 127610A1
Authority
AR
Argentina
Prior art keywords
antibody
conjugate
production
peptide conjugate
peptide
Prior art date
Application number
ARP220103063A
Other languages
English (en)
Inventor
Jonathan Diep
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR127610A1 publication Critical patent/AR127610A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a células de mamífero modificadas para proporcionar una escisión reducida de péptidos que se conjugarán con polipéptidos expresados por las células. En particular, la invención se refiere a un método de producción de un conjugado de anticuerpo-péptido, comprendiendo el método: a) expresar el anticuerpo en una célula de mamífero en el que la célula de mamífero es un célula con inactivación de catepsina D, y en el que el anticuerpo comprende una sustitución de aminoácido de aminoácido no canónico o de cisteína en uno o más sitios de conjugación; b) purificar el anticuerpo; y c) conjugar un péptido con el anticuerpo en el/los sitio(s) de conjugación.
ARP220103063A 2021-11-09 2022-11-08 Método de producción de un conjugado de anticuerpo-péptido AR127610A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163277597P 2021-11-09 2021-11-09

Publications (1)

Publication Number Publication Date
AR127610A1 true AR127610A1 (es) 2024-02-14

Family

ID=86337527

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103063A AR127610A1 (es) 2021-11-09 2022-11-08 Método de producción de un conjugado de anticuerpo-péptido

Country Status (10)

Country Link
EP (1) EP4429710A1 (es)
KR (1) KR20240103014A (es)
CN (1) CN118401257A (es)
AR (1) AR127610A1 (es)
AU (1) AU2022386314A1 (es)
CA (1) CA3236923A1 (es)
IL (1) IL312643A (es)
MX (1) MX2024005709A (es)
TW (1) TW202328201A (es)
WO (1) WO2023086790A1 (es)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
USRE45721E1 (en) 1994-08-20 2015-10-06 Gendaq, Ltd. Relating to binding proteins for recognition of DNA
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
EP1060261B1 (en) 1998-03-02 2010-05-05 Massachusetts Institute of Technology Poly zinc finger proteins with improved linkers
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20030044787A1 (en) 2000-05-16 2003-03-06 Joung J. Keith Methods and compositions for interaction trap assays
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2006272634B2 (en) 2005-07-26 2013-01-24 Sangamo Therapeutics, Inc. Targeted integration and expression of exogenous nucleic acid sequences
US20210238628A1 (en) * 2018-05-04 2021-08-05 Sigma-Aldrich Co. Llc Engineered cells with modified host cell protein profiles

Also Published As

Publication number Publication date
KR20240103014A (ko) 2024-07-03
TW202328201A (zh) 2023-07-16
AU2022386314A1 (en) 2024-06-06
CN118401257A (zh) 2024-07-26
EP4429710A1 (en) 2024-09-18
IL312643A (en) 2024-07-01
CA3236923A1 (en) 2023-05-19
MX2024005709A (es) 2024-07-04
WO2023086790A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
PE20060816A1 (es) Proceso para la concentracion de anticuerpos y productos terapeuticos de los mismos
CY1110734T1 (el) Μεθοδος παραγωγης μονιμων ανθρωπινων κυτταρικων σειρων
DK1844150T3 (da) Rekombinant ekspression af proteiner i en to-kædet form med disulfidbroer
CL2018000238A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
HRP20171202T1 (hr) Nove molekule jnk inhibitora
EA200700292A1 (ru) Полипептиды с повышенной экспрессией
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
CO6251278A2 (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol
NZ603712A (en) Antibodies containing therapeutic tpo/epo mimetic peptides
DK1532261T3 (da) Fremgangsmåder og DNA-konstrukter til produktion af polypeptider med højt udbytte
AR120644A1 (es) Variante de aminotransferasa de aminoácidos de cadena ramificada y procedimiento de producción de leucina usando la misma
AR070693A1 (es) Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas a partir de la expresion del polipeptido de nitrato 2 (nrt2)
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
AR127610A1 (es) Método de producción de un conjugado de anticuerpo-péptido
CO2023003453A2 (es) Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados
GB0608368D0 (en) Process for making Oligopeptides
PE20210119A1 (es) Anticuerpos anti-apoc3 y metodos de uso de estos
AR058625A1 (es) Produccion recombinante de proteinas de union a heparina
AR118355A1 (es) Métodos de fabricación para producir composiciones de anticuerpos anti-tnf
MX2009013393A (es) Expresion de fragmento de anticuerpo soluble mediante truncamiento de dominio de ch1.
AR122020A1 (es) Sistemas y métodos para la conjugación específica de sitio de proteínas mediada por tirosinasa
CO2023000247A2 (es) Composiciones biespecíficas dirigidas a her-2 y métodos para preparar y usar las mismas
AR076781A1 (es) Proceso para producir estabilizador de vino o zumo de frutas